RECOVERY / PEPTIDE CARD

Thymosin Beta-4

A naturally occurring actin-binding peptide studied in tissue repair and regenerative biology.

PEPTIDE CARDThymosin Beta-4

Reviewed
August 8, 2026

Human evidence

2/5 · Early clinical research

U.S. FDANot FDA approved

2026 WADAProhibited

Inspect 3 sources

On this page

WHAT THE EVIDENCE SAYS

Thymosin Beta-4 evidence summary.

Thymosin beta-4 has early human development work and extensive preclinical biology, but that record does not establish routine systemic recovery use or equivalence to TB-500 products.

Entity type
Native peptideSource snapshot
August 8, 2026Record status
Sources attached

Do not overread this record

Full-length thymosin beta-4, recombinant products, topical formulations, and TB-500 are not interchangeable evidence entities.

01 / CLASSIFICATION

What is Thymosin Beta-4?

Entity typeNative peptide

Research categoryRecovery

Known namesThymosin Beta-4

Editorial unitOne molecule or defined product record

Names, fragments, salts, formulations, routes, and branded products are kept distinct whenever transferring evidence would change the conclusion.

Class: Thymosin-related peptides Class: Repair and extracellular-matrix peptides Goal: Recovery & Tissue Repair

02 / EVIDENCE

Thymosin Beta-4 human and preclinical evidence.

HUMAN

2/5 · Early clinical research

Phase 1 systemic exposure and small phase 2 topical ophthalmic studies exist, but no broad recovery indication is established.

PRECLINICAL

4/5 · Extensive repair biology

Actin binding, cell migration, angiogenesis, and repair models form a substantial preclinical literature.

The five-point bars describe the maturity and depth of the evidence base. They do not score effectiveness, safety, or personal suitability.

03 / STATUS

Thymosin Beta-4 FDA and sport status.

U.S. FDANo FDA-approved thymosin beta-4 drug product identified in the August 2026 source snapshot.

2026 WADAProhibited at all times under the 2026 WADA List (S2), which names thymosin beta-4 and derivatives such as TB-500.

Commercial accessPeptideAgent does not route unapproved research substances to sellers.

Status summaries are educational and time-sensitive. Consult current official labeling and anti-doping resources for a decision.

04 / RESEARCH AREAS

What is Thymosin Beta-4 being studied for?

01Corneal repair

02Tissue repair

03Actin biology

04Cell migration

05 / COMPARISONS

Compare Thymosin Beta-4.

BPC-157 vs Thymosin Beta-4Two tissue-repair research stories compared without translating preclinical signals into recovery claims.TB-500 vs Thymosin Beta-4A marketed fragment name compared with the full-length endogenous peptide it is often confused with.Thymosin Alpha-1 vs Thymosin Beta-4Two distinct thymosin peptides with different biology, research programs, and sport status.GHK-Cu vs Thymosin Beta-4Copper-peptide research compared with full-length thymosin beta-4 research without crossing routes or molecules.

06 / LATEST & DEFINING SOURCES

Thymosin Beta-4 primary and official sources.

Human trial / 2021Phase 1 study of recombinant human thymosin beta-4

PubMed

Human trial / 2015Thymosin beta-4 ophthalmic solution in dry eye

PubMed

WADA / 20262026 Prohibited List

World Anti-Doping Agency

07 / QUESTIONS

Questions about Thymosin Beta-4.

Start with identity, research, human evidence, approval, sport status, and the limits of the current record.

EvidenceWhat is the evidence for Thymosin Beta-4?

Thymosin beta-4 has early human development work and extensive preclinical biology, but that record does not establish routine systemic recovery use or equivalence to TB-500 products.

ResearchWhat is Thymosin Beta-4 being studied for?

Current source-backed research areas include Corneal repair, Tissue repair, Actin biology, Cell migration. These areas describe investigation, not established personal benefit.

FDA statusIs Thymosin Beta-4 FDA approved?

Current U.S. status for Thymosin Beta-4: No FDA-approved thymosin beta-4 drug product identified in the August 2026 source snapshot.

Sport statusIs Thymosin Beta-4 prohibited in sport?

Current sport-status snapshot for Thymosin Beta-4: Prohibited at all times under the 2026 WADA List (S2), which names thymosin beta-4 and derivatives such as TB-500.

Evidence limitsWhat are the main evidence limits for Thymosin Beta-4?

Full-length thymosin beta-4, recombinant products, topical formulations, and TB-500 are not interchangeable evidence entities.